This study will evaluate the safety and tolerability of EG 70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors in patients with NMIBC who have failed BCG therapy and have been recommended to have their bladder removed. Giving the study drug inside the bladder is to expose cells in the lining of the bladder, including your cancerous cells, to genes that may cause an immune response inside the bladder and kill the tumor cells.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Marc Bjurlin
Urology
Clinical or Medical
Interventional
Cancer (Bladder)
22-0761